Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Share Class Description:
WBO:GILD: Ordinary SharesCompare
Compare
Traded in other countries / regions
GILD.USA0QYQ.UKGIS.GermanyGILD.ArgentinaGILD.MexicoGILD.Peru1GILD.ItalyGILD.ChileGILD.AustriaGILD34.Brazil IPO Date
2017-05-22Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.26 | |||||
| Debt-to-EBITDA | 5.93 | |||||
| Interest Coverage | 7.79 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.86 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.3 | |||||
| 3-Year EBITDA Growth Rate | 36.6 | |||||
| 3-Year EPS without NRI Growth Rate | -1.8 | |||||
| 3-Year FCF Growth Rate | -0.3 | |||||
| 3-Year Book Growth Rate | 8.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.18 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.68 | |||||
| 9-Day RSI | 59.27 | |||||
| 14-Day RSI | 59.94 | |||||
| 6-1 Month Momentum % | 38.79 | |||||
| 12-1 Month Momentum % | 19.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 99.33 | |||||
| Days Sales Outstanding | 60.28 | |||||
| Days Payable | 34.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.18 | |||||
| Dividend Payout Ratio | 0.69 | |||||
| 3-Year Dividend Growth Rate | 3.3 | |||||
| Forward Dividend Yield % | 3.2 | |||||
| 5-Year Yield-on-Cost % | 4.16 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 4.76 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.11 | |||||
| Operating Margin % | 27 | |||||
| Net Margin % | 0.45 | |||||
| FCF Margin % | 33.17 | |||||
| ROE % | 0.63 | |||||
| ROA % | 0.22 | |||||
| ROIC % | 10.05 | |||||
| ROC (Joel Greenblatt) % | 21.02 | |||||
| ROCE % | 2.51 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1028.67 | |||||
| Forward PE Ratio | 12.54 | |||||
| PE Ratio without NRI | 20.9 | |||||
| Shiller PE Ratio | 15.44 | |||||
| PEG Ratio | 3.94 | |||||
| PS Ratio | 4.1 | |||||
| PB Ratio | 6.24 | |||||
| Price-to-Free-Cash-Flow | 12.29 | |||||
| Price-to-Operating-Cash-Flow | 11.57 | |||||
| EV-to-EBIT | 115.46 | |||||
| EV-to-Forward-EBIT | 10.86 | |||||
| EV-to-EBITDA | 34.09 | |||||
| EV-to-Forward-EBITDA | 9.6 | |||||
| EV-to-Revenue | 4.72 | |||||
| EV-to-Forward-Revenue | 4.73 | |||||
| EV-to-FCF | 14.17 | |||||
| Price-to-Projected-FCF | 1.19 | |||||
| Price-to-Median-PS-Value | 1.11 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.84 | |||||
| Earnings Yield (Greenblatt) % | 0.87 | |||||
| FCF Yield % | 8.17 | |||||
| Forward Rate of Return (Yacktman) % | 14.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gilead Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 25,932.04 | ||
| EPS (TTM) (€) | 0.071 | ||
| Beta | 0.28 | ||
| Volatility % | 25.39 | ||
| 14-Day RSI | 59.94 | ||
| 14-Day ATR (€) | 1.502102 | ||
| 20-Day SMA (€) | 86.7515 | ||
| 12-1 Month Momentum % | 19.03 | ||
| 52-Week Range (€) | 57.55 - 92.27 | ||
| Shares Outstanding (Mil) | 1,246.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gilead Sciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gilead Sciences Inc Frequently Asked Questions
What is Gilead Sciences Inc(WBO:GILD)'s stock price today?
The current price of WBO:GILD is €87.98. The 52 week high of WBO:GILD is €92.27 and 52 week low is €57.55.
When is next earnings date of Gilead Sciences Inc(WBO:GILD)?
The next earnings date of Gilead Sciences Inc(WBO:GILD) is 2025-02-06 Est..
Does Gilead Sciences Inc(WBO:GILD) pay dividends? If so, how much?
The Dividend Yield %  of Gilead Sciences Inc(WBO:GILD) is 3.18% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(WBO:GILD) was 0.69. The lowest was 0.1. And the median was 0.38. The  Forward Dividend Yield % of Gilead Sciences Inc(WBO:GILD) is 3.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers